{"entity":{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","aka":[],"tldr":"Led NICHE-2, in which almost every mismatch-repair-deficient colon cancer responded to short pre-surgery immunotherapy.","summary":"Myriam Chalabi is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL). Her specialisms are gastrointestinal oncology, neoadjuvant immunotherapy and mismatch-repair-deficient cancers. Her NICHE and NICHE-2 trials showed that a brief course of neoadjuvant nivolumab plus ipilimumab produces pathological responses in nearly all mismatch-repair-deficient colon cancers, reshaping the treatment paradigm. Her New England Journal of Medicine paper on NICHE-2 reported neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chalabi%20M%5BAuthor%5D%20NICHE"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":["msi"],"trials":["niche-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute","institutionId":"nki","specialisms":["Gastrointestinal oncology","Neoadjuvant immunotherapy","Mismatch-repair-deficient cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chalabi%20M%5BAuthor%5D%20NICHE"}],"papers":[{"title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer (NICHE-2)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2400634"},{"title":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICHE-2%20neoadjuvant%20nivolumab%20ipilimumab%20dMMR%20colon%20cancer%20Chalabi%20NEJM%202024"}]},"route":"/people/myriam-chalabi/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"term":[{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"}],"trial":[{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/"}],"paper":[{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/"},{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"}],"idea":[{"id":"idea-fund-organ-preservation-programme","kind":"idea","name":"A funded programme of organ-preservation trials to avoid radical surgery","route":"/ideas/idea-fund-organ-preservation-programme/"},{"id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/"}]}}